All Stories

  1. Cardiovascular Diseases: From Pathophysiology to Novel Therapeutic Approaches
  2. Association of insulin and GH/IGF-1 derangements and heart failure: a narrative review
  3. Insulin Resistance/Hyperinsulinemia Should Be Considered in the Prevention and Treatment of Essential Hypertension
  4. Feature Reviews in Cardiovascular Diseases
  5. Aging of the vascular system: proposal of preventive intervention with known natural substances
  6. COVID-19 vaccinations in adults and evaluation of cardiovascular events: critical methodological issues
  7. Insulin Resistance with Associated Hyperinsulinemia as a Cause of the Development and Worsening of Heart Failure
  8. Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study
  9. Chronically Increased Levels of Circulating Insulin Secondary to Insulin Resistance: A Silent Killer
  10. Insulin Resistance, a Risk Factor for Alzheimer’s Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach
  11. Insulin Resistance/Hyperinsulinemia as an Independent Risk Factor That Has Been Overlooked for Too Long
  12. Insulin Resistance/Hyperinsulinemia, Neglected Risk Factor for the Development and Worsening of Heart Failure with Preserved Ejection Fraction
  13. Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated
  14. A case of adverse reaction to booster dose of COVID-19 vaccination: could D-dimer elevation suggest increased clotting risk?
  15. The Negative Impact of Insulin Resistance/Hyperinsulinemia on Chronic Heart Failure and the Potential Benefits of Its Screening and Treatment
  16. Editorial: Methods in general cardiovascular medicine
  17. A Descriptive Review of the Action Mechanisms of Berberine, Quercetin and Silymarin on Insulin Resistance/Hyperinsulinemia and Cardiovascular Prevention
  18. Early Multi-Target Treatment of Mild-to-Moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin
  19. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview
  20. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
  21. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between Novembe...
  22. Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal
  23. Sustained High D-Dimer in Outpatients Who Have Recovered from Mild to Moderate Coronavirus Disease 2019 (COVID-19)
  24. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations
  25. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial
  26. Efficacy of sildenafil in HIV-related pulmonary arterial hypertension
  27. Response to letter by Wang Q et al. regarding article “Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension”
  28. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension
  29. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature
  30. Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome
  31. Reply:
  32. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome
  33. Insulin resistance: Is it time for primary prevention?
  34. The Importance of Tricuspid Regurgitation and Right Ventricular Overload in ICD/CRT Recipients: Beside the Left, beyond the Left
  35. Endocrine Alterations Are the Main Determinants of Cardiac Remodelling in Restrictive Anorexia Nervosa
  36. Cardiac involvement in active uncomplicated acromegaly
  37. A NUTRACEUTICAL COMBINATION IMPROVES INSULIN SENSITIVITY IN PATIENTS WITH METABOLIC SYNDROME: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
  38. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
  39. Letter by Fazio and Carlomagno Regarding Article, “Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population”
  40. Thyroid Hormones and Cardiovascular System: From Bench to Bedside
  41. Late Onset of Hypoxemia Due to a Pulmonary Arteriovenous Malformation During Selective Estrogen Receptor Modulator Therapy
  42. Cardiovascular and metabolic effects of Berberine
  43. Efficacy and safety of valsartan plus hydroclorothiazide for high blood pressure
  44. Long term combination treatment for severe idiopathic pulmonary arterial hypertension
  45. Usefulness of NT-proBNP in the assessment of patients with aortic or mitral regurgitation
  46. Growth Hormone Deficiency in Patients with Chronic Heart Failure and Beneficial Effects of Its Correction
  47. The GH/IGF-1 Axis and Heart Failure
  48. Myocarditis and dilated cardiomyopathy: possible connections and treatments
  49. Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure
  50. Prehypertension and Elevated Risk of Cardiovascular Disease: Physiopathologic Mechanisms
  51. Association between post-ischemic forearm blood flow and blood pressure response to maximal exercise in well trained healthy young men
  52. Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension
  53. Aerobic exercise performance correlates with post-ischemic flow-mediated dilation of the brachial artery in young healthy men
  54. Tadalafil in Primary Pulmonary Arterial Hypertension
  55. Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning par...
  56. Myocardial contractility and total arterial stiffness in patients with overt hyperthyroidism: acute effects of beta1-adrenergic blockade
  57. Peak exercise oxygen uptake and left ventricular systolic and diastolic function and arterial mechanics in healthy young men
  58. Effects of Thyroid Hormone on the Cardiovascular System
  59. Hyperthyroidism, Subclinical
  60. Subclinical Hypothyroidism and Cardiovascular Risk
  61. Subclinical Thyroid Dysfunction and the Heart
  62. Reactive hyperemia and cardiovascular performance in athletes regularly trained
  63. Prospective Evaluation of Hypertensive Patients with Carotid Kinking and Coiling: An Ultrasonographic 7-Year Study
  64. Cardiovascular Safety of Acute Recombinant Human Thyrotropin Administration to Patients Monitored for Differentiated Thyroid Cancer
  65. The importance of using strict inclusion criteria in subclinical hypothyroid studies
  66. Effects of Subclinical Thyroid Dysfunction on the Heart
  67. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
  68. Patients with Subclinical Cushing’s Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
  69. Subclinical Hypothyroidism and Cardiac Function
  70. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  71. Supraphysiological Doses of GH Induce Rapid Changes in Cardiac Morphology and Function
  72. Aldosterone Receptor Blockade in the Management of Heart Failure
  73. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  74. Effects of Thyroid Hormone on Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism
  75. Mortality in elderly patients with subclinical hyperthyroidism
  76. Mortality in elderly patients with subclinical hyperthyroidism
  77. Growth hormone corrects vascular dysfunction in patients with chronic heart failure
  78. Impact of Hyperthyroidism and Its Correction on Vascular Reactivity in Humans
  79. Does the Growth Factor Approach Have a Future in the Treatment of Human Heart failure?
  80. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients*
  81. Endogenous Subclinical Hyperthyroidism Affects Quality of Life and Cardiac Morphology and Function in Young and Middle-Aged Patients
  82. Growth hormone and cardiac function
  83. The role of the GH-IGF-I axis in the regulation of myocardial growth: from experimental models to human evidence
  84. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  85. Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion
  86. Heart Failure: Potential Benefit of Growth Hormone Therapy
  87. A Direct Role for the Macrophage Low Density Lipoprotein Receptor in Atherosclerotic Lesion Formation
  88. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  89. Left Ventricular Diastolic Dysfunction in Patients with Subclinical Hypothyroidism
  90. Growth Hormone and the Heart
  91. Growth hormone as a potential future therapy for congestive heart failure
  92. Growth Hormone in Heart Failure
  93. Cardiac Effects of Growth Hormone in Physiology and in Heart Failure
  94. Doxorubicin‐induced cardiomyopathy treated with carvedilol
  95. Reentrant Atrioventricular Nodal Tachycardia Induced by Levothyroxine
  96. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy
  97. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  98. Increased Arterial Intima-Media Thickness in Childhood-Onset Growth Hormone Deficiency
  99. Growth hormone and heart performance: A novel mechanism of cardiac wall stress regulation in humans
  100. Prevalence of Carotid Kinking and Coiling in a Population at Risk
  101. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
  102. Growth Hormone in the Treatment of Dilated Cardiomyopathy
  103. Cardiovascular aspects in acromegaly: Effects of treatment
  104. Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: Assessment with radionuclide angiography
  105. A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy
  106. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy.
  107. Long-term growth hormone deficiency as a cause of cardiomyopathy and its reversibility with specific replacement therapy
  108. Cardiac performance: Growth hormone enters the race
  109. Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency
  110. Optimal determination of right ventricular filling dynamics in systemic hypertension
  111. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta- blockade
  112. Pacemaker Malfunction Due to Subcutaneous Emphysema
  113. Growth Hormone and the Heart
  114. Growth hormone and the heart
  115. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement
  116. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly
  117. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine
  118. Cardiac Effects of Long Term Thyrotropin-Suppressive Therapy with Levothyroxine
  119. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
  120. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency
  121. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
  122. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine
  123. Platelet Aggregability in Patients with a VVI Pacemaker
  124. Evidence for biventricular involvement in acromegaly: a Doppler echocardiographic study
  125. Capillary Blood Flow to the Skin of Forearm in Cirrhosis
  126. Influence of atenolol on the relationship between heart rate and qt interval in patients with exercise‐induced myocardial ischemia
  127. Pacemaker Malfunction Due to Subcutaneous Emphysema — A Case Report
  128. Evaluation, by Noninvasive Methods, of the Effects of Acute Loss of Thyroid Hormones on the Heart
  129. Follow‐Up of a Respiratory Rate Modulated Pacemaker
  130. Fourier Analysis in Patients with Different Pacing Modes
  131. Efficacy of Ticlopidine in the Prevention of Thromboembolic Events in Patients with VVI Pacemakers
  132. Cardiac function and sympathetic activity in young diabetics
  133. Cardiac function and sympathetic activity in young diabetics
  134. A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer
  135. Atenolol and Amiodarone: A Comparative Study of Their Anti-Ischaemic Effect
  136. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil
  137. Indapamide and atenolol in the treatment of hypertension: double-blind comparative and combination study
  138. Obesity and cardiac function.